The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Overactive Bladder Treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach ...

参考来源：‘Sumitomo Pharma America. Sumitomo Pharma America announces US FDA approval of Gemtesa (vibegron) for men with overactive bladder symptoms receiving pharmacological therapy for ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA ...

Overactive bladder is a condition characterized by symptoms ... Peete was prescribed Gemtesa, a beta-3 agonist medication that helps control urgency, leaks and frequency. “I’ve been on Gemtesa ...

According to the Mayo Clinic, Overactive bladder “causes sudden urges to ... including information on treatment options, such as GEMTESA® (vibegron). In this exclusive with the Hollywood ...